Drug Discovery

Company launches enhanced cAMP assay development kit, announces partnership

Published in Gene Therapy Weekly, October 14th, 2004

Cisbio international, a developer of HTRF technologies and services used in assay development and drug screening, announced an enhancement to its established biomolecular screening solution, the HTRF-based cAMP (Cyclic AMP) assay kit.

Additionally, the company announced that it has initiated a partnership with Euroscreen, which will use Cisbio's HTRF cAMP assay for the validation of Euroscreen's recombinant cell lines and membranes expressing Gi and Gs coupled receptors (GPCR).

cAMP is one of the most established cell transduction signal elements, and its assessment may be the more appropriate way of investigating molecular events occurring at the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-10-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry